Evidence map›Paper›PMID 39225346›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

2D Differential Metallic Immunopotentiators Drive High Diversity and Capability of Antigen-specific Immunity Against Tumor.

Hongze Ren, Anqi Zhu, Wei Yang, Yiwen Jia, Hui Cheng, Ye Wu, Zhengqi Tang, Weifan Ye, Mayu Sun, Yujie Xie and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. MnOMaterials today. Bio · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hongze RenMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Anqi ZhuDepartment of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200070, China.
Wei YangDepartment of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200092, China.
Yiwen JiaMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Hui ChengMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Ye WuMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Zhengqi TangMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Weifan YeMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Mayu SunLaboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yujie XieMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Meihua YuMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.
Yu ChenMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, China.ORCID 0000-0002-8206-3325

Funding

National Natural Science Foundation of China 22205133National Natural Science Foundation of China 32101146Shanghai Education Development FoundationShanghai Excellent Overseas Young ScientistsShanghai Municipal Education Commission 21SG39Shanghai Pujiang Program 21PJ1404500Shanghai Science and Technology Program 21010500100Shanghai University Animal Ethics Committee YS-2023-134Wenzhou Basic Scientific Research Project Y20220139
6 · The paper itself

Abstract

The therapeutic efficacy of vaccines for treating cancers in clinics remains limited. Here, a rationally designed cancer vaccine by placing immunogenically differential and clinically approved aluminum (Al) or manganese (Mn) in a 2D nanosheet (NS) architecture together with antigens is reported. Structurally optimal NS with a high molar ratio of Mn to Al (MANS-H) features distinctive immune modulation, markedly promoting the influx of heterogeneous innate immune cells at the injection site. Stimulation of multiple subsets of dendritic cells (DCs) significantly increases the levels, subtypes, and functionalities of antigen-specific T cells. MANS-H demonstrates even greater effectiveness in the production of antigen-specific antibodies than the commercial adjuvant (Alhydrogel) by priming T helper (Th)2 cells rather than T follicular helper (Tfh) cells. Beyond humoral immunity, MANS-H evokes high frequencies of antigen-specific Th1 and CD8

Indexed as

Adjuvants, ImmunologicCancer VaccinesAluminumAnimalsDendritic CellsDisease Models, AnimalFemaleManganeseMiceMice, Inbred C57BLNeoplasmsAdjuvants, ImmunologicAluminumCancer VaccinesManganese2D nanosheetsantigen‐specific immunitycancer immunotherapycancer vaccinesmaterial adjuvants

Identifiers

PMID39225346
PMCPMC11516112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.